HC Wainwright & Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:HURA) with a B

TuHURA Biosciences NASDAQ: HURA presented preliminary results from its ongoing open-label Phase 1b s

Preliminary results demonstrate major objective tumor responses in first 3 patients at 6 months Comp

Preliminary results demonstrate major objective tumor responses in first 3 patients at 6 months  Com

Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-ma

Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human

Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno

Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherap

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno

TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the

TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "

TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript

Citizens analyst Silvan Turkcan reiterates TuHURA Biosciences (NASDAQ:HURA) with a Market Outperf

TuHURA Biosciences NASDAQ: HURA outlined plans for its late-stage immuno-oncology pipeline at the Ca

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analy

TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "

TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno

The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA)

TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "

TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "C

Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 resul

Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development TAMPA,

TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.c

Distinguished physician with a career spanning over 29 years in drug development and medical affairs

TuHURA Biosciences, Inc. (NASDAQ: HURA - Get Free Report) dropped 3.1% on Friday. The stock traded a

TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "